What is the product information of Cocostat and Acotinib?

Acalabrutinib (Acalabrutinib) is a new BTK inhibitor developed by a subsidiary of AstraZeneca for the treatment of hematological malignancies. The drug achieves anti-cancer effects by selectively inhibiting the BTK signaling pathway and blocking the survival and proliferation of tumor cells. Compared with the early BTK inhibitor ibrutinib, acotinib has certain advantages in drug selectivity and tolerability, has fewer side effects, and is more suitable for long-term use.

In the Chinese market, the trade name of acotinib is“Kangcoqi”. This means that "Kangcoqi" and "Acotinib" are essentially the same drug, and the only difference lies in the international generic name and the domestic registered trademark. Kangcoqi will be officially approved for marketing in China in 2023. Its indications include relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Its dosage form is oral capsule, and the common specification is 100mg. It is usually recommended to take 100mg twice a day, which is convenient for patients to use regularly in daily life.

As an imported innovative drug, Kangcoqi’s research and development background is closely connected with international clinical research. It has been approved byFDA and EMA in the United States, Europe and other places, and has rich clinical application experience. Overseas studies have shown that its response rate and tolerability are good, and it has better efficacy than traditional BTK inhibitors in some patient groups. Because of this, acotinib has attracted much attention once it was launched in China.

In terms of drug circulation, Kangkeqi has been included in the national medical insurance catalog, which has greatly improved accessibility. Through Medicare payment, patients can obtain the drug at a lower cost over the long term. In addition, the medication of Kangcoqi is relatively safe. Common adverse reactions such as headache, mild gastrointestinal discomfort or blood picture changes can be controlled by adjusting medication or supporting treatment.

Reference materials:https://www.calquence.com/